UCB secures €250M EU loan for CNS R&D
This article was originally published in Scrip
Executive Summary
UCB, the Belgian pharma company, has secured long term loans worth up to €250 million from the European Investment Bank (EIB) to support R&D programmes focusing on CNS diseases. The European Union's bank has already signed over €150 million to UCB with an additional €100 million to be made available in 2013. The major indications targeted by UCB with the finance include epilepsy, Parkinson's disease, multiple sclerosis, fibromyalgia, restless leg syndrome and diabetic neuropathic pain.